Search

Your search keyword '"van der Hoek, Jessica J. F."' showing total 4 results
Start Over Author "van der Hoek, Jessica J. F."
4 results on '"van der Hoek, Jessica J. F."'

1. αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression

Author

Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, Wienke, Judith, Afd Pharmaceutics, Pharmaceutics, Center of Experimental and Molecular Medicine, AII - Cancer immunology, CCA - Cancer biology and immunology, Afd Pharmaceutics, and Pharmaceutics more...

Subjects
T cell, medicine.medical_treatment, Medicine (miscellaneous), Major histocompatibility complex, Article, γδ-T cells, neuroblastoma, Neuroblastoma, Interferon, MHC class I, medicine, Organoid, MHC-I, TEG002, biology, Immunotherapy, medicine.disease, medicine.anatomical_structure, Cancer research, biology.protein, Medicine, immunotherapy, medicine.drug, Extracellular matrix organization
Abstract

Currently ~50% of patients with a diagnosis of high-risk neuroblastoma will not survive due to relapsing or refractory disease. Recent innovations in immunotherapy for solid tumors are highly promising, but the low MHC-I expression of neuroblastoma represents a major challenge for T cell-mediated immunotherapy. Here, we propose a novel T cell-based immunotherapy approach for neuroblastoma, based on the use of TEG002, αβ-T cells engineered to express a defined γδ-T cell receptor, which can recognize and kill target cells independent of MHC-I. In a co-culture killing assay, we showed that 3 out of 6 neuroblastoma organoids could activate TEG002 as measured by IFNγ production. Transcriptional profiling showed this effect correlates with an increased activity of processes involved in interferon signaling and extracellular matrix organization. Analysis of the dynamics of organoid killing by TEG002 over time confirmed that organoids which induced TEG002 activation were efficiently killed independent of their MHC-I expression. Of note, efficacy of TEG002 treatment was superior to donor-matched untransduced αβ-T cells or endogenous γδ-T cells. Our data suggest that TEG002 may be a promising novel treatment option for a subset of neuroblastoma patients. more...

Published
2021

2. This title is unavailable for guests, please login to see more information.

Author

Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, Wienke, Judith, Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, and Wienke, Judith more...

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results

3. This title is unavailable for guests, please login to see more information.

Author

Afd Pharmaceutics, Pharmaceutics, Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, Wienke, Judith, Afd Pharmaceutics, Pharmaceutics, Strijker, Josephine G M, Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J F, Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R, Kholosy, Waleed M, Cornel, Annelisa M, Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M, Molenaar, Jan J, and Wienke, Judith more...

Published
2021

4. Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Author

Langenberg KPS, van Hooff SR, Koopmans B, Strijker JGM, Kholosy WM, Ober K, Zwijnenburg DA, van der Hoek JJF, Keller KM, Vernooij L, Schild LG, Looze EJ, Ebus ME, Essing AHW, Vree P, Tas ML, Matser YAH, Wienke J, Volckmann R, Tops BBJ, Kester LA, Badloe S, Hehir-Kwa JY, Kemmeren P, Goemans BF, Zwaan CM, Oehme I, Jäger N, Witt O, van Eijkelenburg NKA, Dierselhuis MP, Tytgat GAM, Wijnen MHW, van Noesel MM, de Krijger RR, Eising S, Koster J, Dolman EM, and Molenaar JJ more...

Subjects
Humans, Cell Line, Tumor, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm genetics, Genomics methods, Neuroblastoma drug therapy, Neuroblastoma genetics, Neuroblastoma pathology, Precision Medicine methods, Organoids drug effects, Organoids pathology, Drug Screening Assays, Antitumor methods, High-Throughput Screening Assays methods
Abstract

Introduction: Despite druggable events to be present in 80 % of neuroblastomapatients within the Princess Máxima Center precision medicine program 'iTHER', clinical uptake of treatment recommendations has been low, and the clinical impact for individual patients remains hard to predict. This stresses the need for a method integrating genomics and transcriptomics with functional approaches into therapeutic decision making., Methods: We aimed to launch an online repository integrating genomics and transcriptomics with high-throughput drug screening (HTS) of nineteen commonly used neuroblastoma cell lines and fifteen neuroblastoma patient-derived organoids (NBL-PDOs). Cell lines, NBL-PDOs and their parental tumors were characterized utilizing (lc)WGS, WES and RNAseq. Cells were exposed to ∼200 compounds. Results were transferred to the R2 visualization platform., Results: A powerful reference set of cell lines is available, reflecting distinct known pharmacologic vulnerabilities. HTS identified additional therapeutic vulnerabilities, such as a striking correlation between a positive mesenchymal signature and sensitivity to BCL2-inhibitor venetoclax. Finally, we explored personalized drug sensitivities within iTHER, demonstrating HTS can support genomic and transcriptomic results, thereby strengthening the rationale for clinical uptake., Conclusion: We established a dynamic publicly available dataset with detailed genomic, transcriptomic, and pharmacological annotation of classical neuroblastoma cell lines as well as novel sharable NBL-PDOs, representing the heterogeneous landscape of neuroblastoma. We anticipate that in vitro drug screening will be complementary to genomic-guided precision medicine by supporting clinical decision making, thereby improving prognosis for all neuroblastoma patients in the future., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.) more...

Published
2025
Full Text
View/download PDF